Fig. 4From: Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trialMedians and IQRs for biochemical markers of bone metabolism at 18 months of the trialBack to article page